Overview
- Pfizer reached deals with Dexcel Pharma, Hikma and Cipla that extend Vyndamax’s effective U.S. patent date to June 1, 2031, subject to the outcome of other lawsuits, for a pill that treats a rare heart disease called transthyretin amyloid cardiomyopathy.
- Pfizer now expects U.S. Vyndamax revenue to stay relatively stable from 2028 through mid‑2031 after previously warning of a decline starting in 2029 when exclusivity was set to end.
- The settlements resolve Pfizer’s patent cases in the U.S. District Court for the District of Delaware against those three companies, while a separate infringement suit with Apotex remains active.
- Vyndamax remains the market leader with about 75% of prescriptions in ATTR‑CM, and Pfizer’s tafamidis franchise generated roughly $6.38–$6.4 billion in global sales in 2025.
- Regulators and critics scrutinize brand–generic settlements that can delay lower‑cost copies, a concern that looms large given Vyndamax’s U.S. list price of more than $250,000 a year.